Results 211 to 220 of about 364,170 (283)

Development of Methods to Produce SARS CoV‐2 Virus‐Like Particles at Scale

Biotechnology and Bioengineering, Volume 122, Issue 5, Page 1118-1129, May 2025.
ABSTRACT The devastating global toll precipitated by the SARS CoV‐2 outbreak and the profound impact of vaccines in stemming that outbreak has established the need for molecular platforms capable of rapidly delivering effective, safe and accessible medical interventions in pandemic preparedness.
Melissa A. Edeling, Linda Earnest, Julio Carrera Montoya, Ashley Huey Yiing Yap, Jamie Mumford, Jason Roberts, Chinn Yi Wong, Dhiraj Hans, Joseph Grima, Nicole Bisset, Jesse Bodle, Steven Rockman, Joseph Torresi   +12 more
wiley   +1 more source

Development of a Monocyte Activation Test for Evaluating Recombinant Hepatitis B Vaccine: A Novel Approach for Pyrogen Assessment. [PDF]

Iran Biomed J
Doroud D, Eftekhari Z, Daneshi M, Gheibi P, Jabbari N, Khatami M, Hosseini M.   +6 more
europepmc   +1 more source

Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease [PDF]

, 2001
Mehmet Arslan, Russell H. Wiesner, Corey Sievers, Kathleen S. Egan, Nizar N. Zein   +4 more
openalex   +1 more source

Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan‐Sarbecoviruses

MedComm, Volume 6, Issue 5, May 2025.
Multispecific antibodies harness the advantages of two or more mAbs. In this study, we designed novel trispecific antibodies, Tri‐1 and Tri‐2, derived from our previously identified mAbs, PW5‐5, PW5‐535, and PW5‐570. These trispecific antibodies exhibited enhanced binding affinity and broad neutralization capacity against SARS‐CoV, SARS‐CoV‐2 variants,
Rui Qiao, Yuanchen Liu, Qiyu Mao, Jiayan Li, Yinying Lu, Jialu Shi, Chen Li, Jizhen Yu, Jiami Gong, Xun Wang, Yuchen Shao, Lei Sun, Wenhong Zhang, Hongjie Yu, Hin Chu, Pengfei Wang, Xiaoyu Zhao   +16 more
wiley   +1 more source

Immune response to GeneVac-B^Ⓡ (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso. [PDF]

IJID Reg
Ouattara NGM, Sanou AM, Napon-Zongo D, Coulibaly A, Korogho S, Dera A, Nikièma AS, Kyelem E, Gansoré N, Ilboudo AK, Diendéré J, Ouédraogo GH.   +11 more
europepmc   +1 more source

Hepatitis B vaccine: Risks and benefits of universal neonatal vaccination [PDF]

, 2001
C. Raina MacIntyre
openalex   +1 more source

Sustainability and Performance Evaluation in Third Sector Partnerships: The Case of Turin Fast Track City

Financial Accountability &Management, Volume 41, Issue 2, Page 381-397, May 2025.
ABSTRACT COVID‐19 radically changed how public services (activities of general interest) are pursued and administered. The search for resilient models has prompted public administration to test new regulatory approaches and to involve the third sector in the provision of primary services. This study investigates the sustainability and capacity of these
Stefano Amelio, Patrizia Gazzola, Paolo Biancone, Valerio Brescia   +3 more
wiley   +1 more source

The hepatitis B vaccine: Sorting through the B.S. about M.S [PDF]

, 2001
Stephen D. Zucker
openalex   +1 more source

Cost‐Effectiveness of Universal Screen‐and‐Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High‐Endemicity City

Journal of Viral Hepatitis, Volume 32, Issue 5, May 2025.
ABSTRACT In the setting of high hepatitis B virus (HBV) endemicity, we studied the cost‐effectiveness of universal HBV screen‐and‐treat strategies for averting HBV‐related morbidity and mortality in Hong Kong, where diagnosis and treatment coverages are low.
Ngai Sze Wong, Denise Pui‐Chung Chan, Grace Lai‐Hung Wong, Shui Shan Lee   +3 more
wiley   +1 more source

Hepatitis B vaccine among healthcare workers: factors associated with the dimensions of the Health Belief Model. [PDF]

Rev Bras Epidemiol
Farias Junior YC, Souza FO, Santos DVD, Heliotério MC, Pinho PS, Araújo TM.   +5 more
europepmc   +1 more source